메뉴 건너뛰기




Volumn 22, Issue SUPPL. 1, 2011, Pages

The clinical development of inhibitors of poly(ADP-ribose) polymerase

Author keywords

BRCA; Cancer; Poly(ADP ribose) polymerase inhibitors

Indexed keywords

4 IODO 3 NITROBENZAMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; AG 14361; AG 14447; ANTINEOPLASTIC AGENT; BMN 673; BRCA1 PROTEIN; CARBOPLATIN; CEP 9722; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; GEMCITABINE; GPI 21016; INIPARIB; INO 1001; IRINOTECAN; MELPHALAN; MK 4827; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIMUSTINE; OLAPARIB; OXALIPLATIN; PF 01367338; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB;

EID: 79551652531     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq667     Document Type: Article
Times cited : (48)

References (56)
  • 1
    • 0035902108 scopus 로고    scopus 로고
    • Genome maintenance mechanisms for preventing cancer
    • Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-374.
    • (2001) Nature , vol.411 , pp. 366-374
    • Hoeijmakers, J.H.1
  • 4
    • 33646582299 scopus 로고    scopus 로고
    • Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway
    • Chirnomas D, Taniguchi T, de la Vega M et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 2006; 5: 952-961.
    • (2006) Mol Cancer Ther , vol.5 , pp. 952-961
    • Chirnomas, D.1    Taniguchi, T.2    de la Vega, M.3
  • 5
    • 52949096470 scopus 로고    scopus 로고
    • Genetic predisposition to breast cancer: past, present, and future
    • Turnbull C, Rahman N. Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 2008; 9: 321-345.
    • (2008) Annu Rev Genomics Hum Genet , vol.9 , pp. 321-345
    • Turnbull, C.1    Rahman, N.2
  • 6
    • 40349108598 scopus 로고    scopus 로고
    • On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations
    • Simon R, Zhang X. On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations. Int J Cancer 2008; 122: 1916-1917.
    • (2008) Int J Cancer , vol.122 , pp. 1916-1917
    • Simon, R.1    Zhang, X.2
  • 7
    • 77950650763 scopus 로고    scopus 로고
    • Germline BRCA mutations denote a clinicopathologic subset of prostate cancer
    • Gallagher DJ, Gaudet MM, Pal P et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010; 16: 2115-2121.
    • (2010) Clin Cancer Res , vol.16 , pp. 2115-2121
    • Gallagher, D.J.1    Gaudet, M.M.2    Pal, P.3
  • 8
    • 62849118739 scopus 로고    scopus 로고
    • Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers. melanoma
    • Mai PL, Chatterjee N, Hartge P et al. Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers. melanoma. PloS one 2009; 4: e4812.
    • (2009) PloS one , vol.4
    • Mai, P.L.1    Chatterjee, N.2    Hartge, P.3
  • 9
    • 64949184079 scopus 로고    scopus 로고
    • A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma
    • Kefford RF, Thomas NP, Corrie PG et al. A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. Br J Cancer 2009; 100: 1245-1249.
    • (2009) Br J Cancer , vol.100 , pp. 1245-1249
    • Kefford, R.F.1    Thomas, N.P.2    Corrie, P.G.3
  • 11
    • 0018906390 scopus 로고
    • (ADP-ribose)n participates in DNA excision repair
    • Durkacz BW, Omidiji O, Gray DA et al. (ADP-ribose)n participates in DNA excision repair. Nature 1980; 283: 593-596.
    • (1980) Nature , vol.283 , pp. 593-596
    • Durkacz, B.W.1    Omidiji, O.2    Gray, D.A.3
  • 12
    • 0019844233 scopus 로고
    • Inhibitors of nuclear ADP-ribosyl transferase retard DNA-repair after N-methyl-N-nitroso-urea - further evidence for the involvement of (ADP-ribose)n in DNA-repair
    • Gray DA, Durkacz BW, Shall S. Inhibitors of nuclear ADP-ribosyl transferase retard DNA-repair after N-methyl-N-nitroso-urea - further evidence for the involvement of (ADP-ribose)n in DNA-repair. FEBS Lett 1981; 131: 173-177.
    • (1981) FEBS Lett , vol.131 , pp. 173-177
    • Gray, D.A.1    Durkacz, B.W.2    Shall, S.3
  • 13
    • 0033941729 scopus 로고    scopus 로고
    • Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines
    • Delaney CA, Wang LZ, Kyle S et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000; 6: 2860-2867.
    • (2000) Clin Cancer Res , vol.6 , pp. 2860-2867
    • Delaney, C.A.1    Wang, L.Z.2    Kyle, S.3
  • 14
    • 12444276597 scopus 로고    scopus 로고
    • Identification of potent non-toxic novel poly(ADP-ribose)polymerase-1 inhibitors. Chemopotentiation and pharmacological studies
    • Calabrese CR, Batey MA, Thomas HD et al. Identification of potent non-toxic novel poly(ADP-ribose)polymerase-1 inhibitors. Chemopotentiation and pharmacological studies. Clini Cancer Res 2003; 9: 2711-2718.
    • (2003) Clini Cancer Res , vol.9 , pp. 2711-2718
    • Calabrese, C.R.1    Batey, M.A.2    Thomas, H.D.3
  • 15
    • 59449085305 scopus 로고    scopus 로고
    • Phase I study of the poly (ADPribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors
    • Plummer R, Jones C, Middleton M et al. Phase I study of the poly (ADPribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 7917-7923.
    • (2008) Clin Cancer Res , vol.14 , pp. 7917-7923
    • Plummer, R.1    Jones, C.2    Middleton, M.3
  • 16
    • 17244375049 scopus 로고    scopus 로고
    • Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
    • Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917.
    • (2005) Nature , vol.434 , pp. 913-917
    • Bryant, H.E.1    Schultz, N.2    Thomas, H.D.3
  • 17
    • 17244373777 scopus 로고    scopus 로고
    • Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
    • Farmer H, McCabe1 N, Lord C et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
    • (2005) Nature , vol.434 , pp. 917-921
    • Farmer, H.1    McCabe1, N.2    Lord, C.3
  • 18
    • 67650476607 scopus 로고    scopus 로고
    • Synthetic lethality-a new direction in cancer-drug development
    • Iglehart JD, Silver DP. Synthetic lethality-a new direction in cancer-drug development. N Engl J Med 2009; 361: 189-191.
    • (2009) N Engl J Med , vol.361 , pp. 189-191
    • Iglehart, J.D.1    Silver, D.P.2
  • 19
    • 33947380240 scopus 로고    scopus 로고
    • Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology
    • Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007; 13: 1383-1388.
    • (2007) Clin Cancer Res , vol.13 , pp. 1383-1388
    • Ratnam, K.1    Low, J.A.2
  • 20
    • 0037151051 scopus 로고    scopus 로고
    • Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1
    • Schreiber V, AmeJC Dolle P et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 2002; 277: 23028-23036.
    • (2002) J Biol Chem , vol.277 , pp. 23028-23036
    • Schreiber, V.1    Ame, J.C.2    Dolle, P.3
  • 21
    • 0034733694 scopus 로고    scopus 로고
    • Base excision repair in yeast and mammals
    • Memisoglu A, Samson L. Base excision repair in yeast and mammals. Mutat Res 2000; 451: 39-51.
    • (2000) Mutat Res , vol.451 , pp. 39-51
    • Memisoglu, A.1    Samson, L.2
  • 22
    • 34147182310 scopus 로고    scopus 로고
    • Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
    • Thomas HD, Calabrese CR, Batey MA et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 2007; 6: 945-956.
    • (2007) Mol Cancer Ther , vol.6 , pp. 945-956
    • Thomas, H.D.1    Calabrese, C.R.2    Batey, M.A.3
  • 23
    • 70349659952 scopus 로고    scopus 로고
    • Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?
    • Ali M, Telfer BA, McCrudden C et al. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin Cancer Res 2009; 15: 6106-6112.
    • (2009) Clin Cancer Res , vol.15 , pp. 6106-6112
    • Ali, M.1    Telfer, B.A.2    McCrudden, C.3
  • 25
    • 38949141134 scopus 로고    scopus 로고
    • Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells
    • Azzariti A, Porcelli L, Gatti G et al. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochem Pharmacol 2008; 75: 1035-1044.
    • (2008) Biochem Pharmacol , vol.75 , pp. 1035-1044
    • Azzariti, A.1    Porcelli, L.2    Gatti, G.3
  • 26
    • 10744233628 scopus 로고    scopus 로고
    • Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repairdeficient cells
    • Curtin NJ, Wang LZ, Yiakouvaki A et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repairdeficient cells. Clin Cancer Res 2004; 10: 881-889.
    • (2004) Clin Cancer Res , vol.10 , pp. 881-889
    • Curtin, N.J.1    Wang, L.Z.2    Yiakouvaki, A.3
  • 27
    • 63149128657 scopus 로고    scopus 로고
    • Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma
    • Daniel RA, Rozanska AL, Thomas HD et al. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res 2009; 15: 1241-1249.
    • (2009) Clin Cancer Res , vol.15 , pp. 1241-1249
    • Daniel, R.A.1    Rozanska, A.L.2    Thomas, H.D.3
  • 28
    • 54549103449 scopus 로고    scopus 로고
    • 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phth alazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1
    • Menear KA, Adcock C, Boulter R et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phth alazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008; 51: 6581-6591.
    • (2008) J Med Chem , vol.51 , pp. 6581-6591
    • Menear, K.A.1    Adcock, C.2    Boulter, R.3
  • 29
    • 55949092708 scopus 로고    scopus 로고
    • High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
    • Rottenberg S, Jaspers JE, Kersbergen A et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008; 105: 17079-17084.
    • (2008) Proc Natl Acad Sci USA , vol.105 , pp. 17079-17084
    • Rottenberg, S.1    Jaspers, J.E.2    Kersbergen, A.3
  • 30
    • 33751278712 scopus 로고    scopus 로고
    • Cellular functions of the BRCA tumoursuppressor proteins
    • Boulton SJ. Cellular functions of the BRCA tumoursuppressor proteins. Biochem Soc Trans 2006; 34: 633-645.
    • (2006) Biochem Soc Trans , vol.34 , pp. 633-645
    • Boulton, S.J.1
  • 31
    • 52449111109 scopus 로고    scopus 로고
    • Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin
    • Evers B, Drost R, Schut E et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14: 3916-3925.
    • (2008) Clin Cancer Res , vol.14 , pp. 3916-3925
    • Evers, B.1    Drost, R.2    Schut, E.3
  • 32
    • 65949095892 scopus 로고    scopus 로고
    • Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin
    • Hay T, Matthews JR, Pietzka L et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009; 69: 3850-3855.
    • (2009) Cancer Res , vol.69 , pp. 3850-3855
    • Hay, T.1    Matthews, J.R.2    Pietzka, L.3
  • 33
    • 74949093142 scopus 로고    scopus 로고
    • A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors
    • Evers B, Schut E, van der Burg E et al. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res 2010; 16: 99-108.
    • (2010) Clin Cancer Res , vol.16 , pp. 99-108
    • Evers, B.1    Schut, E.2    van der Burg, E.3
  • 34
    • 76749114340 scopus 로고    scopus 로고
    • Sensitivity and acquired resistance of BRCA1; p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan
    • Zander SA, Kersbergen A, van der Burg E et al. Sensitivity and acquired resistance of BRCA1; p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res 2010; 70: 1700-1710.
    • (2010) Cancer Res , vol.70 , pp. 1700-1710
    • Zander, S.A.1    Kersbergen, A.2    van der Burg, E.3
  • 35
    • 34249006299 scopus 로고    scopus 로고
    • ABT-888, an orally active poly(ADPribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
    • Donawho CK, Luo Y, Penning TD et al. ABT-888, an orally active poly(ADPribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13: 2728-2737.
    • (2007) Clin Cancer Res , vol.13 , pp. 2728-2737
    • Donawho, C.K.1    Luo, Y.2    Penning, T.D.3
  • 36
    • 54249167431 scopus 로고    scopus 로고
    • Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of singlestranded DNA damages to double-stranded DNA breaks
    • Liu X, Shi Y, Guan R et al. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of singlestranded DNA damages to double-stranded DNA breaks. Mol Cancer Res 2008; 6: 1621-1629.
    • (2008) Mol Cancer Res , vol.6 , pp. 1621-1629
    • Liu, X.1    Shi, Y.2    Guan, R.3
  • 37
    • 68849128273 scopus 로고    scopus 로고
    • Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity
    • Horton TM, Jenkins G, Pati D et al. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 2009; 8: 2232-2242.
    • (2009) Mol Cancer Ther , vol.8 , pp. 2232-2242
    • Horton, T.M.1    Jenkins, G.2    Pati, D.3
  • 38
    • 73149110553 scopus 로고    scopus 로고
    • ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors
    • Palma JP, Wang YC, Rodriguez LE et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 2009; 15: 7277-7290.
    • (2009) Clin Cancer Res , vol.15 , pp. 7277-7290
    • Palma, J.P.1    Wang, Y.C.2    Rodriguez, L.E.3
  • 39
    • 60849125726 scopus 로고    scopus 로고
    • Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
    • Clarke MJ, Mulligan EA, Grogan PT et al. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther 2009; 8: 407-414.
    • (2009) Mol Cancer Ther , vol.8 , pp. 407-414
    • Clarke, M.J.1    Mulligan, E.A.2    Grogan, P.T.3
  • 40
    • 72449148827 scopus 로고    scopus 로고
    • Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways
    • Liu X, Han EK, Anderson M et al. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol Cancer Res 2009; 7: 1686-1692.
    • (2009) Mol Cancer Res , vol.7 , pp. 1686-1692
    • Liu, X.1    Han, E.K.2    Anderson, M.3
  • 41
    • 33644675410 scopus 로고    scopus 로고
    • Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft
    • Cheng CL, Johnson SP, Keir ST et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005; 4: 1364-1368.
    • (2005) Mol Cancer Ther , vol.4 , pp. 1364-1368
    • Cheng, C.L.1    Johnson, S.P.2    Keir, S.T.3
  • 42
    • 77954951941 scopus 로고    scopus 로고
    • Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma
    • Toshimitsu H, Yoshimoto Y, Augustine CK et al. Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma. Ann Surg Oncol 2010; 17: 2247-2254.
    • (2010) Ann Surg Oncol , vol.17 , pp. 2247-2254
    • Toshimitsu, H.1    Yoshimoto, Y.2    Augustine, C.K.3
  • 43
    • 38149076469 scopus 로고    scopus 로고
    • INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin
    • Mason KA, Valdecanas D, Hunter NR, Milas L. INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Invest New Drugs 2008; 26: 1-5.
    • (2008) Invest New Drugs , vol.26 , pp. 1-5
    • Mason, K.A.1    Valdecanas, D.2    Hunter, N.R.3    Milas, L.4
  • 44
    • 79551577948 scopus 로고    scopus 로고
    • A review of PARP inhibitors: from bench to bedside
    • Jul 19 [Epub ahead of print]
    • Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol 2010; Jul 19 [Epub ahead of print].
    • (2010) Ann Oncol
    • Underhill, C.1    Toulmonde, M.2    Bonnefoi, H.3
  • 45
    • 68449096428 scopus 로고    scopus 로고
    • Efficacy of BSI-201, a poly(ADPribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial
    • (Abstr 3)
    • O'Shaughnessy J, Osborne C, Pippen J et al. Efficacy of BSI-201, a poly(ADPribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009; 27: (Suppl 18): 793s (Abstr 3).
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL. 18
    • O'Shaughnessy, J.1    Osborne, C.2    Pippen, J.3
  • 47
    • 33947379595 scopus 로고    scopus 로고
    • PARP inhibitors enhance the effect of cisplatin against tumors and ameliorate cisplatin-induced neuropathy
    • Lapidus RG, XuW Spicer E et al. PARP inhibitors enhance the effect of cisplatin against tumors and ameliorate cisplatin-induced neuropathy. Proc Am Assoc Cancer Res 2006; 47: A2141.
    • (2006) Proc Am Assoc Cancer Res , vol.47
    • Lapidus, R.G.1    Spicer, E.2    Xu, W.3
  • 48
    • 34548072788 scopus 로고    scopus 로고
    • The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity
    • Miknyoczki S, Chang H, Grobelny J et al. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther 2007; 6: 2290-2302.
    • (2007) Mol Cancer Ther , vol.6 , pp. 2290-2302
    • Miknyoczki, S.1    Chang, H.2    Grobelny, J.3
  • 49
    • 10744226451 scopus 로고    scopus 로고
    • Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361
    • Calabrese CR, Almassy R, Barton S et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004; 96: 56-67.
    • (2004) J Natl Cancer Inst , vol.96 , pp. 56-67
    • Calabrese, C.R.1    Almassy, R.2    Barton, S.3
  • 50
    • 35148894301 scopus 로고    scopus 로고
    • First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). Meeting Abstracts Part I
    • (Abstr 8013)
    • Plummer R, Lorigan P, Evans J et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). Meeting Abstracts Part I. J Clin Oncol 2006; 24 (Suppl 18): 456S (Abstr 8013).
    • (2006) J Clin Oncol , vol.24 , Issue.SUPPL. 18
    • Plummer, R.1    Lorigan, P.2    Evans, J.3
  • 51
    • 67650471685 scopus 로고    scopus 로고
    • Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
    • Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
    • (2009) N Engl J Med , vol.361 , pp. 123-134
    • Fong, P.C.1    Boss, D.S.2    Yap, T.A.3
  • 52
    • 77955019276 scopus 로고    scopus 로고
    • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
    • Tutt A, Robson M, Garber JE. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244.
    • (2010) Lancet , vol.376 , pp. 235-244
    • Tutt, A.1    Robson, M.2    Garber, J.E.3
  • 53
    • 77955039099 scopus 로고    scopus 로고
    • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
    • Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251.
    • (2010) Lancet , vol.376 , pp. 245-251
    • Audeh, M.W.1    Carmichael, J.2    Penson, R.T.3
  • 54
    • 77951445939 scopus 로고    scopus 로고
    • Poly(ADP-ribose) polymerase inhibitors: a novel drug class with a promising future
    • Gartner EM, Burger AM, LoRusso PM. Poly(ADP-ribose) polymerase inhibitors: a novel drug class with a promising future. Cancer J 2010; 16: 83-90.
    • (2010) Cancer J , vol.16 , pp. 83-90
    • Gartner, E.M.1    Burger, A.M.2    LoRusso, P.M.3
  • 55
    • 39849097680 scopus 로고    scopus 로고
    • Resistance to therapy caused by intragenic deletion in BRCA2
    • doi: 10.1038/nature06548
    • Edwards SL, Brough R, Lord CJ et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451: doi: 10.1038/nature06548.
    • (2008) Nature , pp. 451
    • Edwards, S.L.1    Brough, R.2    Lord, C.J.3
  • 56
    • 0029782022 scopus 로고    scopus 로고
    • Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy. University of Texas M. D. Anderson Cancer Center Experience
    • Diamandidou E, Au Buzdar, Smith TL et al. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy. University of Texas M.D. Anderson Cancer Center Experience. J Clin Oncol. 1996; 14: 2722-2730.
    • (1996) J Clin Oncol , vol.14 , pp. 2722-2730
    • Diamandidou, E.1    Buzdar, Au.2    Smith, T.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.